NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
May 31, 2025 — Researchers unveil RADICAL, a cutting-edge chemogenetic tool for precise neuronal control using cyclohexanol. This breakthrough in neuroscience offers new possibilities for research and therapy in neurological disorders.
May 31, 2025 — Discover the groundbreaking research uncovering the dynamic architecture of the pyruvate dehydrogenase complex (PDHc) and its implications for metabolic disease research. Learn how this study could revolutionize therapeutic strategies for PDHc-related disorders and pave the way for advances in structural biology and drug development.
May 30, 2025 — Adageis introduces AI-powered solutions for healthcare providers transitioning to value-based care, including the ProActive Care Platform with predictive analytics. Learn how Adageis is revolutionizing healthcare delivery and improving patient outcomes.
May 30, 2025 — New study reveals link between autism spectrum disorder and Parkinson's disease, highlighting shared biological mechanisms. Clene Inc. (NASDAQ: CLNN) could benefit from this research. Learn more about the study findings and implications here.
May 30, 2025 — Scinai Immunotherapeutics (SCNI) reports Q1 2025 financial results with revenue growth and decreased net loss. Learn more about the biopharmaceutical company's performance and innovative pipeline.
May 30, 2025 — Lantern Pharma reports strong preclinical data for LP-184 in treating pediatric brain cancer, showing promising results for ATRT therapy. The findings could lead to significant advancements in the treatment of this rare and aggressive cancer.
May 30, 2025 — Quantum BioPharma (QNTM) settles disputes with former CEO, Dr. Raza Bokhari, injecting $2.35M into the business. The agreement provides financial stability and focuses on drug development for neurodegenerative disorders like multiple sclerosis.
May 30, 2025 — The American Council of the Blind shows support for crucial legislation concerning early detection and intervention for children with vision impairments. Learn about the See the Board Act and the Early Detection of Vision Impairments (EDVI) Act and how they can impact the lives of visually impaired children. Take action by contacting Congressmembers to push these bills forward.
May 29, 2025 — Telomir Pharmaceuticals announces positive preclinical results for Telomir-1 in reversing retinal degeneration in zebrafish model of AMD. Learn how this breakthrough could lead to regenerative treatments for macular degeneration.
May 29, 2025 — Unbuzzd Wellness Inc. appoints MNP LLP for PCAOB audits in preparation for a potential IPO, demonstrating commitment to transparency and financial diligence. Follow the company's journey towards capital raising and public listing advisory.
May 29, 2025 — American Heart Association encourages CPR training for families to ensure a heart-healthy summer. Learn how to save lives with CPR, supported by Walgreens. Improve survival rates for cardiac arrest and be prepared for emergencies.
May 29, 2025 — Alzamend Neuro is making strides in developing transformative therapies for Alzheimer’s, BD, MDD, and PTSD. Learn about their breakthrough treatments and the potential impact on patients' lives.
May 29, 2025 — SeaStar Medical reports significant growth in QUELIMMUNE sales and sets sights on the adult AKI market. The company's innovative therapy shows promise for improving patient outcomes and could have a substantial impact on the healthcare industry.
May 29, 2025 — University of Houston receives $3 million grant for cancer immunotherapy biomarker core from Cancer Prevention & Research Institute of Texas. This investment showcases the commitment to innovative cancer research.
May 29, 2025 — Alzamend Neuro announces dosing of first patient in Phase II trial of AL001, a lithium-based therapeutic for Alzheimer’s, bipolar disorder, MDD, and PTSD. Learn more about this breakthrough treatment here.
May 29, 2025 — GeoVax supports bipartisan effort to bring vaccine manufacturing back to the U.S., emphasizing the significance of national health security and pandemic preparedness. The company's MVA platform is at the forefront of advancing multi-antigen vaccines for high-risk populations.
May 29, 2025 — Glucotrack Inc. is set to host a virtual webinar discussing its groundbreaking Continuous Blood Glucose Monitor (CBGM) technology, offering insights into the future of diabetes management. Learn how this innovation could reshape traditional glucose monitoring methods and improve the lives of millions affected by diabetes.
May 28, 2025 — TransCode Therapeutics appoints Dr. Phillip D. Zamore, a leading figure in RNA research, to its Scientific Advisory Board. The addition enhances the company's focus on RNA-targeted cancer therapy programs, marking a strategic development in the fight against metastatic disease.
May 28, 2025 — Bioadaptives showcases remarkable clinical results for Regen(TM) Dog Chews, offering a safe and effective solution for improving canine health and vitality. With a 281.3% increase in circulating stem cells and a proprietary rating system, this premium pet wellness product stands out for its natural ingredients and proven benefits.
May 28, 2025 — TransCode Therapeutics appoints Dr. Phillip D. Zamore, a leading figure in RNA research, to its Scientific Advisory Board, enhancing its cancer therapy programs. The addition of Dr. Zamore underscores the company's commitment to developing innovative RNA therapeutics for metastatic disease.